Mei pharma, inc. (MEIP)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10
Research and development revenue

-

-

-

-

-

-

-

-

-

-

283

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License revenue

-

-

-

-

-

-

-

-

-

-

-

-

3,779

17,101

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development revenue

-

-

-

-

-

-

-

-

-

-

-

-

726

98

1,096

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue

1,244

1,008

1,157

1,130

1,249

2,048

488

548

433

358

283

449

4,505

17,199

1,096

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses:
Cost of revenue

860

641

688

1,102

1,163

1,009

989

1,107

930

728

618

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of research and development revenue

-

-

-

-

-

-

-

-

-

-

-

-

1,147

1,771

1,094

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

8,963

8,281

8,962

8,032

9,071

9,066

6,131

4,459

3,071

3,444

6,064

2,073

1,876

1,642

1,646

3,985

3,420

3,182

2,816

3,779

6,775

6,703

6,566

6,414

5,415

4,400

3,102

1,651

1,543

1,338

1,552

1,320

1,490

1,061

1,044

381

298

751

685

General and administrative

3,864

4,195

4,130

3,744

3,631

3,821

3,401

2,455

2,486

2,358

2,488

1,826

2,152

1,970

2,680

1,836

1,990

1,945

1,830

1,909

2,185

2,415

2,439

2,146

1,991

1,949

1,811

1,581

1,225

1,418

914

883

811

896

889

806

1,033

1,352

1,145

Total operating expenses

13,687

13,117

13,780

12,878

13,865

13,896

10,521

8,021

6,487

6,530

9,170

4,887

5,175

5,383

5,420

5,821

5,410

5,127

4,646

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,410

5,127

-

-

8,960

9,118

9,005

8,560

7,406

6,349

4,913

3,232

2,768

2,756

2,466

2,203

2,301

1,957

1,933

1,187

1,331

2,103

1,830

Loss from operations

-12,443

-12,109

-12,623

-11,748

-12,616

-11,848

-10,033

-7,473

-6,054

-6,172

-8,887

-4,438

-670

11,816

-4,324

-5,821

-5,410

-5,127

-4,646

-5,688

-8,960

-9,118

-9,005

-8,560

-7,406

-6,349

-4,913

-3,232

-2,768

-2,756

-2,466

-2,203

-2,301

-1,957

-1,933

-1,187

-1,331

-2,103

-1,830

Other income (expense):
Change in fair value of warrant liability

7,732

-8,439

9,269

14,358

-5,201

23,437

-4,962

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest and dividend income

382

318

374

443

462

436

454

292

106

93

100

95

68

69

55

51

39

26

27

26

30

10

12

19

19

25

18

17

15

2

3

2

32

2

3

5

19

35

71

Other income (expense)

0

13

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other expense

-

-

14

-

-

-

1

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Adjustments to fair value of derivatives

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

423

716

-

-

-

-

Financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

9

397

-

-

-

-

Income tax expense

-

-

-

-

-

-

-

0

0

0

1

0

0

0

1

0

0

0

1

-

-

1

-

0

0

0

1

0

0

0

1

0

0

0

1

-

-

-

-

Net loss

-4,329

-20,217

-2,994

3,053

-17,355

12,025

-14,542

-19,253

-5,948

-6,079

-8,788

-4,343

-602

11,885

-4,270

-5,770

-5,371

-5,101

-4,620

-5,662

-8,930

-9,109

-8,993

-8,541

-7,387

-6,324

-4,896

-

-

-

-

-

-

-

-

-

-

-

-

Net loss:
Basic and diluted

-

-

-2,994

-

-

-

-14,542

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic

-4,329

-20,217

-

-

-17,355

12,025

-

-

-5,948

-6,079

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

-4,329

-20,217

-

-

-17,355

-11,412

-

-

-5,948

-6,079

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share:
Net loss arising during development stage

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,753

-2,754

-2,464

-

-2,269

-1,541

-1,612

-1,642

-1,312

-2,068

-1,759

Basic and diluted

-

-

-0.04

-

-

-

-0.21

-

-

-

-

-

-

-

-

-

-0.16

-0.15

-0.13

-

-0.27

-0.39

-0.42

-0.40

-0.34

-0.32

-0.29

-0.10

0.17

-0.47

-0.70

-2.25

-0.15

-0.78

-0.17

-0.19

-0.18

-0.28

-0.24

Basic

-0.04

-0.26

-

-

-0.24

0.17

-

-0.41

-0.16

-0.16

-0.24

-0.11

-0.02

0.32

-0.12

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

-0.04

-0.26

-

-

-0.24

-0.15

-

-0.41

-0.16

-0.16

-0.24

-0.11

-0.02

0.32

-0.12

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares used in computing net loss per share:
Basic

105,999

78,577

-

-

71,200

71,124

-

53,616

37,449

37,414

37,245

37,161

37,172

37,172

35,747

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

105,999

78,577

-

-

71,200

73,951

-

53,616

37,449

37,414

37,245

37,616

37,172

37,217

35,747

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted

-

-

73,628

-

-

-

70,885

-

-

-

-

-

-

-

-

-

34,422

34,422

34,334

-

33,471

23,584

21,652

21,559

21,502

20,067

17,116

16,819

14,868

5,455

3,499

-17,245

14,668

1,979

9,588

8,435

7,445

7,346

7,346